CTMX
CytomX Therapeutics Inc
NASDAQ: CTMX · HEALTHCARE · BIOTECHNOLOGY
$4.05
-1.70% today
Updated 2026-04-29
Market cap
$951.18M
P/E ratio
—
P/S ratio
12.48x
EPS (TTM)
$-0.15
Dividend yield
—
52W range
$1 – $8
Volume
7.6M
CytomX Therapeutics Inc (CTMX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-8.01M | $31.80M | $-27.41M | $-2.03M | $170.37M | $-75.52M | $-140.48M | $5.26M | $-119.03M | $-110.79M | $-56.03M | $-86.23M | $-75.59M |
| Capital expenditures | $732000.00 | $1.66M | $1.59M | $2.18M | $1.56M | $3.79M | $3.50M | $2.31M | $1.61M | $1.74M | $840000.00 | $310000.00 | $220000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $343000.00 | $553000.00 | $3.99M | $10.10M | $11.29M | $16.88M | $19.10M | $14.79M | $13.17M | $13.17M | $8.56M | $7.67M | $6.30M |
| Free cash flow | $-8.74M | $30.14M | $-29.01M | $-4.21M | $168.81M | $-79.31M | $-143.98M | $2.95M | $-120.64M | $-112.53M | $-56.88M | $-86.54M | $-75.81M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | $6.71M | $0.00 | $0.00 | — | — | — | — | — | — | — | $3.00M |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | $44.82M | $72.90M | $70.03M | $-59.15M | $3.43M | $13.67M | $13.67M | — | — | — |